DMYD B.ST Stock Analysis
DM
Uncovered
Diamyd Medical AB is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Diamyd Medical AB engages in the development of pharmaceutical products for the treatment of diabetes and other serious inflammatory diseases. The company is headquartered in Stockholm, Stockholm and currently employs 20 full-time employees. The company went IPO on 2013-05-20. The company is active in the field of pharmaceutical development and investments in stem cell and medical technology. The firm develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.